Safety of continuous nebulized albuterol for bronchospasm in infants and children

R. W. Katz, H. W. Kelly, M. R. Crowley, Roni Grad, B. C. McWilliams, S. J. Murphy

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm. Design. Prospective, case series. Setting. A university pediatric intensive care and pediatric subacute units. Patients. Nineteen infants and children who received CNA for at least 24 hours. Interventions. None. Measurements. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was ≥250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy. Main results. Creatinine phosphokinase levels remained within normal limits for 16 patients during CNA treatment. Three patients had elevated CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythmias were noted during CNA therapy, even in the patients with elevated CK-MB fractions. Conclusions. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined.

Original languageEnglish (US)
Pages (from-to)666-669
Number of pages4
JournalPediatrics
Volume92
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Bronchial Spasm
Albuterol
Safety
Creatinine
Electrocardiography
Phosphotransferases
Therapeutics
Pediatric Intensive Care Units
Isoenzymes
Cardiac Arrhythmias
Ischemia
Pediatrics
Incidence

Keywords

  • arrhythmia
  • bronchospasm
  • cardiotoxicity
  • continuous nebulization
  • creatinine phosphokinase
  • myocardial ischemia
  • talbuterol

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Katz, R. W., Kelly, H. W., Crowley, M. R., Grad, R., McWilliams, B. C., & Murphy, S. J. (1993). Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics, 92(5), 666-669.

Safety of continuous nebulized albuterol for bronchospasm in infants and children. / Katz, R. W.; Kelly, H. W.; Crowley, M. R.; Grad, Roni; McWilliams, B. C.; Murphy, S. J.

In: Pediatrics, Vol. 92, No. 5, 1993, p. 666-669.

Research output: Contribution to journalArticle

Katz, RW, Kelly, HW, Crowley, MR, Grad, R, McWilliams, BC & Murphy, SJ 1993, 'Safety of continuous nebulized albuterol for bronchospasm in infants and children', Pediatrics, vol. 92, no. 5, pp. 666-669.
Katz RW, Kelly HW, Crowley MR, Grad R, McWilliams BC, Murphy SJ. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics. 1993;92(5):666-669.
Katz, R. W. ; Kelly, H. W. ; Crowley, M. R. ; Grad, Roni ; McWilliams, B. C. ; Murphy, S. J. / Safety of continuous nebulized albuterol for bronchospasm in infants and children. In: Pediatrics. 1993 ; Vol. 92, No. 5. pp. 666-669.
@article{02628f7701b4425bb7e337e273f087a3,
title = "Safety of continuous nebulized albuterol for bronchospasm in infants and children",
abstract = "Objective. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm. Design. Prospective, case series. Setting. A university pediatric intensive care and pediatric subacute units. Patients. Nineteen infants and children who received CNA for at least 24 hours. Interventions. None. Measurements. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was ≥250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy. Main results. Creatinine phosphokinase levels remained within normal limits for 16 patients during CNA treatment. Three patients had elevated CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythmias were noted during CNA therapy, even in the patients with elevated CK-MB fractions. Conclusions. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined.",
keywords = "arrhythmia, bronchospasm, cardiotoxicity, continuous nebulization, creatinine phosphokinase, myocardial ischemia, talbuterol",
author = "Katz, {R. W.} and Kelly, {H. W.} and Crowley, {M. R.} and Roni Grad and McWilliams, {B. C.} and Murphy, {S. J.}",
year = "1993",
language = "English (US)",
volume = "92",
pages = "666--669",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Safety of continuous nebulized albuterol for bronchospasm in infants and children

AU - Katz, R. W.

AU - Kelly, H. W.

AU - Crowley, M. R.

AU - Grad, Roni

AU - McWilliams, B. C.

AU - Murphy, S. J.

PY - 1993

Y1 - 1993

N2 - Objective. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm. Design. Prospective, case series. Setting. A university pediatric intensive care and pediatric subacute units. Patients. Nineteen infants and children who received CNA for at least 24 hours. Interventions. None. Measurements. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was ≥250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy. Main results. Creatinine phosphokinase levels remained within normal limits for 16 patients during CNA treatment. Three patients had elevated CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythmias were noted during CNA therapy, even in the patients with elevated CK-MB fractions. Conclusions. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined.

AB - Objective. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm. Design. Prospective, case series. Setting. A university pediatric intensive care and pediatric subacute units. Patients. Nineteen infants and children who received CNA for at least 24 hours. Interventions. None. Measurements. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was ≥250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy. Main results. Creatinine phosphokinase levels remained within normal limits for 16 patients during CNA treatment. Three patients had elevated CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythmias were noted during CNA therapy, even in the patients with elevated CK-MB fractions. Conclusions. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined.

KW - arrhythmia

KW - bronchospasm

KW - cardiotoxicity

KW - continuous nebulization

KW - creatinine phosphokinase

KW - myocardial ischemia

KW - talbuterol

UR - http://www.scopus.com/inward/record.url?scp=0027425720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027425720&partnerID=8YFLogxK

M3 - Article

C2 - 8414852

AN - SCOPUS:0027425720

VL - 92

SP - 666

EP - 669

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -